News | Drug-Eluting Balloons | March 06, 2019

MedAlliance Granted FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon

Drug-eluting balloon catheter delivers sirolimus with an extended release profile similar to drug-eluting stents

Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for Selution, its sustained limus release (SLR) drug-eluting balloon (DEB) catheter, for the treatment of coronary disease.

March 6, 2019 – Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for Selution, its sustained limus release (SLR) drug-eluting balloon (DEB) catheter, for the treatment of coronary disease.

Selution’s technology involves micro-reservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These micro-reservoirs provide controlled and sustained release of sirolimus. Extended release of sirolimus from stents has been demonstrated highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT (Cellular Adhesive Technology) enables the micro-reservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.

MedAlliance is reportedly the first and only company able to deliver sirolimus in a DEB with an extended release profile similar to that of a drug-eluting stent (DES). Preclinical animal data shows therapeutic levels of sirolimus in tissue for greater than 60 days, and first-in-man clinical trial results in peripheral arteries demonstrate a late lumen loss of 0.19mm.

The FDA received the MedAlliance request to designate Selution as a Breakthrough Device in January 2019. The proposed indications for use included “improving luminal diameter, after pre-dilatation, in treatment of coronary artery ISR for stenotic lengths up to 36 mm with reference vessel diameters of 2.25 - 4.5 mm."

The goal of the Breakthrough Devices Program is to provide patients and healthcare providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency's mission to protect and promote public health.

The Breakthrough Devices Program offers manufacturers an opportunity to interact with the FDA's experts through several different program options to efficiently address topics as they arise during the premarket review phase, which can help manufacturers receive feedback from the FDA and identify areas of agreement in a timely way. Manufacturers can also expect prioritized review of their submission.

For more information: www.ma-medalliance.com

Related Content

News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Technology | Balloon Catheter

August 23, 2018 — W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance ...

Home August 23, 2018
Home
Technology | Balloon Catheter

March 21, 2018 — Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) ...

Home March 21, 2018
Home
News | Balloon Catheter

January 24, 2018 — Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product ...

Home January 24, 2018
Home
News | Balloon Catheter

May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports of ...

Home May 22, 2017
Home
Subscribe Now